Search Results - "Dorst, C. H."

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension by van Doorn, Leni, Visser, Wesley J., van Dorst, Daan C. H., Mirabito Colafella, Katrina M., Koolen, Stijn L. W., de Mik, Anneke van Egmond, Garrelds, Ingrid M., Bovée, Dominique M., de Hoop, Esther Oomen, Bins, Sander, Eskens, Ferry A. L. M., Hoorn, Ewout J., Jan Danser, A. H., Mathijssen, Ron H. J., Versmissen, Jorie

“…Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension…”
Get full text

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study by van Dorst, Daan C H, Kabadayi, Sumeyye, Oomen-de Hoop, Esther, Danser, A H Jan, Mathijssen, Ron H J, Versmissen, Jorie

“…Background Anti-cancer vascular endothelial growth factor inhibitors (VEGFI) frequently induce a rise in blood pressure (BP). The most effective treatment of…”
Get full text

Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment by van Dorst, Daan C.H., de Wagenaar, Nathalie P., van der Pluijm, Ingrid, Roos-Hesselink, Jolien W., Essers, Jeroen, Danser, A.H. Jan

“…Thoracic aortic aneurysms (TAAs) are permanent pathological dilatations of the thoracic aorta, which can lead to life-threatening complications, such as aortic…”
Get full text

A domain-independent descriptive design model and its application to structured reflection on design processes by Reymen, I. M. M. J., Hammer, D. K., Kroes, P. A., van Aken, J. E., Dorst, C. H., Bax, M. F. T., Basten, T.

“…Domain-independent models of the design process are an important means for facilitating interdisciplinary communication and for supporting multidisciplinary…”
Get full text

Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association by Cohen, Jordana B., Brown, Nancy J., Brown, Sherry-Ann, Dent, Susan, van Dorst, Daan C.H., Herrmann, Sandra M., Lang, Ninian N., Oudit, Gavin Y., Touyz, Rhian M.

“…Contemporary anticancer drugs have significantly improved cancer survival at the expense of cardiovascular toxicities, including heart disease, thromboembolic…”
Get full text

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients by van Dorst, Daan C.H., Dobbin, Stephen J.H., Neves, Karla B., Herrmann, Joerg, Herrmann, Sandra M., Versmissen, Jorie, Mathijssen, Ron H.J., Danser, A.H. Jan, Lang, Ninian N.

“…The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has…”
Get full text

Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment by van Dorst, Daan C H, Mirabito Colafella, Katrina M, van Veghel, Richard, Garrelds, Ingrid M, de Vries, René, Mathijssen, Ron H J, Danser, A H Jan, Versmissen, Jorie

“…Anticancer angiogenesis inhibitors cause hypertension and renal injury. Previously we observed in rats that high-dose aspirin (capable of blocking…”
Get full text

Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk? by van Dorst, Daan C H, van Doorn, Leni, Mirabito Colafella, Katrina M, Manintveld, Olivier C, Hassing, H Carlijne, Danser, A H Jan, Mathijssen, Ron H J, Versmissen, Jorie

“…In the past two decades, treatment outcomes for a wide range of malignancies have improved remarkably due to the development of novel anti-cancer therapies,…”
Get more information

Prevention of VEGF inhibitor-induced toxicity by salt restriction: the SUN-SALT study by Van Doorn, L, Visser, W J, Van Dorst, D C H, Mirabito Colafella, K M M, Koolen, S L W, Van Egmond-De Mik, A M E, Oomen-De Hoop, E, Bins, S, Hoorn, E J, Danser, A H, Mathijssen, A H, Versmissen, J

“…Abstract Introduction Vascular endothelial growth factor (VEGF) inhibitors target the formation of new blood vessels required for growth and metastatic spread…”
Get full text

The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer by Buijs, Sanne M., van Dorst, Daan C.H., Kruip, Marieke J.H.A., van den Akker, Rob F.P., Cheung, Ka L., Porrazzo, Robert, Oomen-de Hoop, Esther, Jager, Agnes, Koolen, Stijn L.W., Versmissen, Jorie, Jan Danser, A.H., Versteeg, Henri H., Bos, Mettine H.A., Mathijssen, Ron H.J.

“…Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins,…”
Get full text